Product Description
Mechanisms of Action: Protease Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: China | India | Ukraine
Approved Indications: None
Known Adverse Events: None
Company: Zhejiang University
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Congenital Heart Defects|Injuries/wounds Unspecified|Other|Coronary Artery Disease|Reperfusion Injury|Inflammation|Shock, Septic|Pancreatitis
Phase 3: Oral Ulcer|Nasopharyngeal Cancer|Stomatitis|Mucositis|Sepsis
Phase 2: COVID-19|Acute Lung Injury|Respiratory Distress Syndrome, Newborn|Lung Injury|Respiratory Aspiration|Acute Respiratory Distress Syndrome
Phase 1: Acute Lung Injury
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| ChiCTR2300074837 | N/A |
Recruiting |
Kidney Diseases|Acute Kidney Injury|Coronary Disease |
2033-08-31 |
2024-01-14 |
Treatments |
|
| PANDA XI | N/A |
Enrolling by invitation |
Aortic Aneurysm |
2026-12-31 |
2025-05-14 |
Primary Endpoints |
|
| ChiCTR2500095855 | N/A |
Recruiting |
Spinal Stenosis|Spondylolisthesis |
2026-12-31 |
|||
| ChiCTR2300072139 | N/A |
Recruiting |
Pancreatitis, Acute |
2026-06-30 |
2023-06-09 |
Treatments |
|
| ChiCTR2500103934 | N/A |
Recruiting |
Unknown |
2026-06-09 |
|||
| ChiCTR2400080349 | N/A |
Not yet recruiting |
Sepsis |
2025-12-31 |
2024-01-27 |
Treatments |
|
| ChiCTR2400091262 | N/A |
Not yet recruiting |
Pancreatitis, Acute |
2025-07-01 |
|||
| The application of Ulinastatin in postoperative analgesia following knee/hip arthroplasty. | N/A |
Not yet recruiting |
Acute Pain|Pain, Postoperative |
2025-06-30 |
|||
| ChiCTR2300079180 | N/A |
Recruiting |
Unknown |
2025-06-01 |
2023-12-27 |
Treatments |
|
| ChiCTR2500102668 | N/A |
Recruiting |
Pancreatitis, Acute |
2025-05-31 |
|||
| ChiCTR2500097826 | N/A |
Recruiting |
Pain, Postoperative|Morphine Dependence |
2025-05-31 |
|||
| ChiCTR2200058102 | N/A |
Not yet recruiting |
Inflammation |
2024-12-31 |
2023-03-12 |
Treatments |
|
| TJ-IRB20220831 | N/A |
Completed |
Kidney Diseases|Acute Kidney Injury|Pulmonary Heart Disease|Edema, Cardiac|Pulmonary Edema|Coronary Artery Disease|Hypertension, Pulmonary|Animal Hypersensitivity|Dyslipidemia|Environmental Hypersensitivity|Stroke|Drug Hypersensitivity|Anesthesia Related|Cardiac Arrest |
2024-12-30 |
2025-01-22 |
Primary Endpoints |
|
| ChiCTR2300072126 | N/A |
Not yet recruiting |
Pain, Postoperative |
2024-05-30 |
2023-07-29 |
Treatments |
|
| ChiCTR2300074039 | N/A |
Recruiting |
Pain, Postoperative |
2024-03-31 |
2023-11-04 |
Patient Enrollment |
|
| ChiCTR2200057974 | N/A |
Not yet recruiting |
Meningioma|Brain Cancer|Brain Edema |
2023-12-31 |
|||
| ChiCTR2000035702 | N/A |
Recruiting |
Acute Respiratory Distress Syndrome |
2023-12-31 |
|||
| ChiCTR2200059084 | N/A |
Recruiting |
Cognitive Dysfunction |
2023-12-31 |
|||
| ChiCTR2100043950 | N/A |
Recruiting |
Cognitive Dysfunction |
2023-12-31 |
|||
| ChiCTR2300072391 | N/A |
Recruiting |
Pancreatic Cancer |
2023-12-31 |
2023-06-14 |
Treatments |
|
| ChiCTR2200057516 | N/A |
Recruiting |
Other |
2023-12-30 |
|||
| ChiCTR2300067404 | N/A |
Not yet recruiting |
Oxidative Stress|Reperfusion Injury |
2023-11-30 |
|||
| MUNI-SEP | P4 |
Unknown status |
Shock, Septic |
2023-10-01 |
2025-05-03 |
Primary Endpoints |
|
| ChiCTR2100053208 | N/A |
Recruiting |
Cognitive Dysfunction |
2023-07-01 |
|||
| ChiCTR2100052282 | N/A |
Not yet recruiting |
Unknown |
2023-06-30 |